Search research articles
Contact Us
Filters
Showing results (361-370 of 372) with videos related to
Page
of 38
Sort By:
Lancet (London, England)
|
June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Nature Communications
|
December 5, 2025
Taming harmful bursts and heat flux in high-confinement tokamak plasmas
Q M Hu, H Q Wang, M Navarro, et al.
Nature Cancer
|
October 31, 2023
Structural surfaceomics reveals an AML-specific conformation of integrin β<sub>2</sub> as a CAR T cellular therapy target
Kamal Mandal, Gianina Wicaksono, Clinton Yu, et al.
Blood
|
May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study
Lori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Blood Advances
|
May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement
Ibrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Transplantation and Cellular Therapy
|
June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances
|
June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Tamer Othman, Gregory W Roloff, Katharine Miller, et al.
Blood Advances
|
October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Yannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances
|
August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Page
of 38
Search research articles
Search
Showing results (361-370 of 372) with videos related to
Sort By:
Page
of 38
Lancet (London, England)
|
June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Nature Communications
|
December 5, 2025
Taming harmful bursts and heat flux in high-confinement tokamak plasmas
Q M Hu, H Q Wang, M Navarro, et al.
Nature Cancer
|
October 31, 2023
Structural surfaceomics reveals an AML-specific conformation of integrin β<sub>2</sub> as a CAR T cellular therapy target
Kamal Mandal, Gianina Wicaksono, Clinton Yu, et al.
Blood
|
May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study
Lori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Blood Advances
|
May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement
Ibrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Transplantation and Cellular Therapy
|
June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances
|
June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Tamer Othman, Gregory W Roloff, Katharine Miller, et al.
Blood Advances
|
October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Yannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances
|
August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Page
of 38